An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer - PubMed (original) (raw)
An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer
R Nishimura et al. Oncology. 2000 Aug.
Abstract
Treatment of advanced or recurrent breast cancer with medroxyprogesterone acetate (MPA) shows high response rates and the accessory effects of appetite stimulation, improvement in performance status (PS) and bone marrow protection. In recent years, interleukin-6 (IL-6) has been reported to cause cachexia. In this study, to clarify the significance of IL-6 in advanced or recurrent breast cancer, the relationship between the IL-6 level and clinical findings or effect of MPA was investigated. Sixty-five patients with recurrent or advanced breast cancer participated in a prospective study. The age of patients ranged from 28 to 79 years with an average age of 51.3 years. IL-6 level was investigated in these patients dosed with 800 mg/day of MPA and in 17 postoperative nonrecurrent patients. Serum MPA level was measured by high-performance liquid chromatography and IL-6 level was measured prior to MPA administration, 4 weeks (in 59 cases) and 12 weeks (in 32 patients) after MPA administration by ELISA. Serum IL-6 level was significantly higher in recurrent cases, especially in those with visceral metastasis. Further, in patients for whom MPA therapy was effective, the IL-6 level prior to the treatment was clearly low. The IL-6 level was significantly increased after 4 weeks. However, response to MPA was significantly higher and PS was improved in those cases demonstrating less increased IL-6 levels after 4 weeks. In addition, the effect of MPA was significantly related to a higher serum concentration of MPA-positive ER, and longer disease-free interval, although there was no significant predictive factor for the clinical effect of MPA therapy in multivariate analysis. In conclusion, MPA therapy was effective in cases demonstrating a low IL-6 level and less increased IL-6 levels after 4 weeks. PS was improved in those cases in which the degree of IL-6 increase was suppressed by MPA, and many such cases showed low IL-6 levels prior to MPA therapy. Furthermore, PS was improved even in nonresponders to MPA. Therefore, it is suggested that MPA therapy might be useful in treating recurrent breast cancer, and its benefits might be mediated by IL-6.
Copyright 2000 S. Karger AG, Basel.
Similar articles
- Medroxyprogesterone acetate treatment reduces serum interleukin-6 levels in patients with metastatic breast carcinoma.
Yamashita J, Hideshima T, Shirakusa T, Ogawa M. Yamashita J, et al. Cancer. 1996 Dec 1;78(11):2346-52. Cancer. 1996. PMID: 8941005 - Predictive value of serum medroxyprogesterone acetate concentration for response in advanced or recurrent breast cancer.
Nishimura R, Nagao K, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Higuchi A, Ikeda K. Nishimura R, et al. Eur J Cancer. 1997 Aug;33(9):1407-12. doi: 10.1016/s0959-8049(97)00125-1. Eur J Cancer. 1997. PMID: 9337682 Clinical Trial. - A randomized controlled comparative study of oral medroxyprogesterone acetate 1,200 and 600 mg in patients with advanced or recurrent breast cancer.
Koyama H, Tominaga T, Asaishi K, Abe R, Iino Y, Enomoto K, Miura S, Nomura Y, Nakazato H, Abe O. Koyama H, et al. Oncology. 1999;56(4):283-90. doi: 10.1159/000011979. Oncology. 1999. PMID: 10343191 Clinical Trial. - [Hormonal therapy for endometrial adenocarcinoma].
Susumu N, Aoki D, Suzuki N, Nozawa S. Susumu N, et al. Gan To Kagaku Ryoho. 2001 Jul;28(7):934-45. Gan To Kagaku Ryoho. 2001. PMID: 11478142 Review. Japanese. - Medroxyprogesterone acetate and cancer cachexia: interleukin-6 involvement.
Yamashita JI, Ogawa M. Yamashita JI, et al. Breast Cancer. 2000;7(2):130-5. doi: 10.1007/BF02967444. Breast Cancer. 2000. PMID: 11029784 Review.
Cited by
- Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH. Svane IM, et al. Cancer Immunol Immunother. 2007 Sep;56(9):1485-99. doi: 10.1007/s00262-007-0293-4. Epub 2007 Feb 7. Cancer Immunol Immunother. 2007. PMID: 17285289 Free PMC article. Clinical Trial. - Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer.
Noman AS, Uddin M, Chowdhury AA, Nayeem MJ, Raihan Z, Rashid MI, Azad AK, Rahman ML, Barua D, Sultana A, Shirin A, Ferdous J, Parag RR, Rahman SM, Mahmud MR, Jerin CS, Jahan N, Siddiqua A, Ara T, Sabur EB, Alam SS, Baidya S, Akther S, Rahman MZ, Banu T, Murugan AK, Sabri S, Islam SMS, Karakas B, Aboussekhra A, Yeger H, Farhat WA, Islam SS. Noman AS, et al. Sci Rep. 2017 May 11;7(1):1796. doi: 10.1038/s41598-017-01268-4. Sci Rep. 2017. PMID: 28496132 Free PMC article. - Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
DeMichele A, Gray R, Horn M, Chen J, Aplenc R, Vaughan WP, Tallman MS. DeMichele A, et al. Cancer Res. 2009 May 15;69(10):4184-91. doi: 10.1158/0008-5472.CAN-08-2989. Epub 2009 May 12. Cancer Res. 2009. PMID: 19435922 Free PMC article. - The Signal Transducer IL6ST (gp130) as a Predictive and Prognostic Biomarker in Breast Cancer.
Martínez-Pérez C, Leung J, Kay C, Meehan J, Gray M, Dixon JM, Turnbull AK. Martínez-Pérez C, et al. J Pers Med. 2021 Jun 29;11(7):618. doi: 10.3390/jpm11070618. J Pers Med. 2021. PMID: 34210062 Free PMC article. Review. - Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.
Adesoye T, Tripathy D, Hunt KK, Keyomarsi K. Adesoye T, et al. Cancers (Basel). 2024 Jan 24;16(3):492. doi: 10.3390/cancers16030492. Cancers (Basel). 2024. PMID: 38339245 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical